Literature DB >> 21475907

Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells.

Guotai Xu1, Cai Zhang, Jian Zhang.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in diverse human cancers, including human lung cancer. In this study, STAT3β, a dominant negative (DN) form of STAT3, was used to block activated STAT3 in human lung cancer cells and to confirm the effects of DN STAT3 on lung cancer cell proliferation and invasion in?vitro. The results showed that the pIRES-STAT3β plasmid is efficiently transfected into and overexpressed in human lung cancer cells. Overexpressed STAT3β specifically blocked STAT3 transcriptional activation, inhibiting the proliferation and augmenting the apoptosis of human lung cancer cells. This was associated with the down-regulation of the anti-apoptotic gene bcl-xl and the cell cycle gene cyclin D1. Additionally, the invasive activity of A549 and PG cells was significantly inhibited by overexpressed STAT3β, and was accompanied by a decrease in matrix metalloproteinase-2 activation. These findings suggest that interfering with the DN STAT3, STAT3β, may induce potent antitumor activity. STAT3? is therefore a potential candidate for the treatment of human lung cancers with high metastasic ability.

Entities:  

Year:  2009        PMID: 21475907     DOI: 10.3892/mmr_00000178

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  14 in total

1.  Antitumorigenic potential of STAT3 alternative splicing modulation.

Authors:  Francesca Zammarchi; Elisa de Stanchina; Eirini Bournazou; Teerawit Supakorndej; Kathryn Martires; Elyn Riedel; Adriana D Corben; Jacqueline F Bromberg; Luca Cartegni
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

Review 2.  Pre-mRNA splicing in disease and therapeutics.

Authors:  Ravi K Singh; Thomas A Cooper
Journal:  Trends Mol Med       Date:  2012-07-18       Impact factor: 11.951

3.  Antisense Modulation of RNA Processing as a Therapeutic Approach in Cancer Therapy.

Authors:  Lee Spraggon; Luca Cartegni
Journal:  Drug Discov Today Ther Strateg       Date:  2013

4.  Systemic administration of a cyclic signal transducer and activator of transcription 3 (STAT3) decoy oligonucleotide inhibits tumor growth without inducing toxicological effects.

Authors:  Malabika Sen; Kathleen Paul; Maria L Freilino; Hua Li; Changyou Li; Daniel E Johnson; Lin Wang; Julie Eiseman; Jennifer R Grandis
Journal:  Mol Med       Date:  2014-03-18       Impact factor: 6.354

5.  Strategy of STAT3β cell-specific expression in macrophages exhibits antitumor effects on mouse breast cancer.

Authors:  W Dang; H Tang; H Cao; L Wang; X Zhang; W Tian; X Pang; K Li; T Chen
Journal:  Gene Ther       Date:  2015-10-01       Impact factor: 5.250

6.  STAT3β is a tumor suppressor in acute myeloid leukemia.

Authors:  Petra Aigner; Tatsuaki Mizutani; Jaqueline Horvath; Thomas Eder; Stefan Heber; Karin Lind; Valentin Just; Herwig P Moll; Assa Yeroslaviz; Michael J M Fischer; Lukas Kenner; Balázs Győrffy; Heinz Sill; Florian Grebien; Richard Moriggl; Emilio Casanova; Dagmar Stoiber
Journal:  Blood Adv       Date:  2019-07-09

Review 7.  The JAK/STAT signaling pathway: from bench to clinic.

Authors:  Xiaoyi Hu; Jing Li; Maorong Fu; Xia Zhao; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-11-26

8.  ZFX knockdown inhibits growth and migration of non-small cell lung carcinoma cell line H1299.

Authors:  Kui Li; Zhi-Chuan Zhu; Yong-Jie Liu; Ji-Wei Liu; Hong-Tao Wang; Zhi-Qi Xiong; Xu Shen; Ze-Lan Hu; Jing Zheng
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

9.  Alterations in microRNAs miR-21 and let-7a correlate with aberrant STAT3 signaling and downstream effects during cervical carcinogenesis.

Authors:  Gauri Shishodia; Shirish Shukla; Yogesh Srivastava; Shashank Masaldan; Sumita Mehta; Suresh Bhambhani; Shashi Sharma; Ravi Mehrotra; Bhudev Chandra Das; Alok Chandra Bharti
Journal:  Mol Cancer       Date:  2015-06-09       Impact factor: 27.401

Review 10.  Oncogenic alternative splicing switches: role in cancer progression and prospects for therapy.

Authors:  Serena Bonomi; Stefania Gallo; Morena Catillo; Daniela Pignataro; Giuseppe Biamonti; Claudia Ghigna
Journal:  Int J Cell Biol       Date:  2013-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.